Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 6
Submit an article Journal homepage
3,018
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

Néboa Zozayaa Department of Health Economics, Weber, Madrid, Spain;b Department of Quantitative Methods in Economics and Management, University Las Palmas de Gran Canaria, Las Palmas, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4618-6894View further author information
ORCID Icon,
Fernando Abdallaa Department of Health Economics, Weber, Madrid, SpainView further author information
,
Santiago Alfonso Zamorac Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, SpainView further author information
,
Jesús Balea Filgueirasd Department of Pharmacy, Ferrol University Hospital Complex, La Coruña, SpainView further author information
,
José Manuel Carrascosa Carrilloe Department of Dermatology, Germans Trias I Pujol University Hospital, Badalona, SpainORCID Iconhttps://orcid.org/0000-0003-4266-0771View further author information
ORCID Icon,
Olga Delgado Sánchezf Department of Management, Spanish Society of Hospital Pharmacy (SEFH). Department of Pharmacy, Son Espases University Hospital, Illes Balears, SpainView further author information
,
Francisco Dolz Sinisterrag Department of Management, Doctor Peset University Hospital, Valencia, SpainView further author information
,
Antonio García-Ruizh Health Economics and Rational Use of Medicines. Department of Pharmacology and Clinical Therapeutics, Biomedical Research Institute of Málaga (IBIMA), University of Málaga, Málaga, SpainORCID Iconhttps://orcid.org/0000-0001-6423-6993View further author information
ORCID Icon,
Pedro Herranz Pintoi Department of Dermatology, La Paz University Hospital, Madrid, SpainView further author information
,
Antonio Manfredic Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, SpainView further author information
,
José Martínez Olmosj Andalusian Public Health School (EASP), Granada, SpainView further author information
,
Paloma Morales de Los Ríos Lunak Department of Nursing, Gregorio Marañón University Hospital, Madrid, SpainView further author information
,
Lluis Puigl Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-6083-0952View further author information
ORCID Icon,
Sandra Rosm Department of Dermatology, Rheumatology and Cardiac Transplantation, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainView further author information
&
Álvaro HIdalgo-Vegan Weber Foundation, Madrid, Spain;o Department of Economic Analysis and Finances, University of Castilla-La Mancha, Toledo, SpainORCID Iconhttps://orcid.org/0000-0003-4088-8027View further author information
ORCID Icon show all
Pages 941-953 | Received 22 Dec 2021, Accepted 05 Apr 2022, Published online: 25 Apr 2022

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer & Lluís Puig. (2023) Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives. Patient Preference and Adherence 17, pages 1541-1549.
Read now

Articles from other publishers (2)

Sonali Batta, Ramlah Khan, Marcus Zaayman, Allison Limmer, Dario Kivelevitch & Alan Menter. (2023) IL-17 and -23 Inhibitors for the Treatment of Psoriasis. EMJ Allergy & Immunology.
Crossref
Néboa Zozaya, Maria Iciar Arrizubieta Basterrechea, Elena Bollo, Iván Castellví, Jaime Espín, Norberto Ortego, José Luis Poveda-Andrés, José Antonio Rodríguez Portal, Agustín Rivero, José Antonio Marcos-Rodríguez & Luis Verde. (2022) A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. International Journal of Technology Assessment in Health Care 38:1.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.